Viva Avac ASF Vaccine Trial in Reproductive Pigs
AVAC Vaccine Shows Promise Against African Swine Fever in Vietnam
Table of Contents
- AVAC Vaccine Shows Promise Against African Swine Fever in Vietnam
- AVAC ASF Vaccine: Your questions Answered
- 1. What is the AVAC ASF LIVE vaccine, and what is it designed to do?
- 2. When was the AVAC ASF LIVE vaccine first authorized for use?
- 3.Is the AVAC ASF LIVE vaccine safe and effective?
- 4. What is the current stage of testing for the AVAC ASF LIVE vaccine?
- 5. What are the key findings from the large-scale testing?
- 6. How is avac ensuring transparency in its research?
- 7. How is AVAC evaluating the vaccine’s impact on reproductive performance?
- 8. What is the recommended vaccination protocol for the AVAC ASF LIVE vaccine?
- 9. What are the future plans for the AVAC ASF LIVE vaccine?
- 10. How long is the vaccine evaluation process?
- 11. What is the significance of extending the vaccine’s use to reproductive pigs?
- 12. What is the General Director’s perspective on the vaccine based on the article?
- 13. Where can I find more facts on current test results?
- 14. Can you provide a summary of key data from the testing?
HUNG YEN, Vietnam – A pilot program evaluating the AVAC ASF LIVE vaccine against African swine fever (ASF) in Vietnam has yielded promising early results, according to the Avac Vietnam Joint Stock Company.The company reported that initial tests on vaccinated pigs demonstrated a strong immune response to the virus.
Vaccine efficacy and Safety
The study, conducted at the Granja de Avac Vietnam Joint Stock Company, involved scientists, livestock companies, veterinary associations, and international organizations. The primary goal is to assess the vaccineS protective capabilities, safety, and its effects on the reproductive performance of sows and boars.
Nguyen Van Diep, General Director of Avac Vietnam Joint Stock Company, stated that the AVAC ASF LIVE vaccine has been authorized for use in pigs since July 2023. “The vaccine has gained the confidence of government and livestock stakeholders due to its demonstrated safety and effectiveness,” Diep said. He added that extending the vaccine’s use to reproductive pigs is a strategic move for the company.
Large-Scale Testing
Over the past two years, Avac’s Research and Development Department has conducted small-scale vaccine trials. In March 2025, the company initiated a large-scale experimental model in collaboration with the Central Center for Diagnosis of Veterinary Medicine and other scientific companies. This model included 270 young sows under controlled experimental conditions.
The first injection was administered on March 11, 2025. According to Diep, initial results were encouraging. As of April 2, 2025, 22 days after the first injection, all 270 pigs, including those receiving a normal dose and those receiving a tenfold overdose, remained healthy and showed no clinical abnormalities.
Antibody Response
Elisa antibody tests revealed that 100% of the vaccinated pigs developed antibodies against the African swine fever virus, indicating a robust immune response. In contrast, control animals that did not receive the vaccine tested negative for antibodies and viremia.
Furthermore,saliva and wastewater samples from vaccinated animals showed no detection of the ASF virus,suggesting a low risk of vaccine virus propagation and confirming the product’s safety during use.
Clarity and Data Sharing
Avac emphasizes transparency in its research. “We are building the experimental model openly and transparently,” Diep said. “We invite scientists,international experts,industry associations,companies,and farmers to monitor the process from the initial injection through subsequent reproductive stages. The goal is to create a comprehensive and transparent dataset on the vaccine’s efficacy, safety, and impact on reproductive performance.”
The company has been researching and monitoring the productivity of vaccinated pigs for over two years.The current model, involving nearly 300 sows, is specifically designed to evaluate reproductive performance post-vaccination.
Avac anticipates inviting stakeholders back to the farm in approximately five months, during the pig breeding period, to directly assess reproductive efficiency and long-term protection levels.
Vaccination Protocol
Avac has developed a vaccination process for sows and boars. young reproductive sows and boars should be vaccinated similarly to other pigs, starting at four weeks of age. Young sows require two injections,spaced three weeks apart,with the second injection administered two weeks before mating.
For pigs that have already reproduced, a booster vaccination is recommended in each reproductive cycle, specifically 1 to 14 days before mating (approximately 2 to 3 weeks after delivery) to ensure continued protection.
future Evaluations
Avac is collaborating with the Central Veterinary Medication Test Center I to establish criteria for evaluating ASF vaccines in reproductive pigs. The company plans to propose official testing of the AVAC ASF LIVE vaccine in reproductive pigs to the Department of Animal Health (Ministry of agriculture and Environment). This evaluation process is expected to take approximately 5 to 6 months.
“After the second injection, we continue to take samples two weeks later, closely monitor the health of pigs, and update the clinical results daily,” Diep said. “We hope that these results will become a reliable source of scientific data for both management agencies and the livestock community.”
Avac is also open to collaboration and data exchange with national and international livestock companies and laboratories to further evaluate the vaccine’s efficacy.
Recently,many farmers have proactively used the Avac ASF vaccine,not only in pigs,but also in sows,obtaining safe results. These field data are the basis for AVAC to implement with confidence a pilot model for more than two years… and also to evaluate the quality of this vaccine in about 270 sows.
Nguyen Van Diep, General Director of Avac Vietnam Joint Stock company
AVAC ASF Vaccine: Your questions Answered
African Swine Fever (ASF) has devastated pig populations worldwide. The development of effective vaccines is crucial to protecting the global pork industry. This article answers frequently asked questions about the AVAC ASF LIVE vaccine, its development, and its potential impact, based on recent reports from the Avac Vietnam Joint Stock Company.
1. What is the AVAC ASF LIVE vaccine, and what is it designed to do?
The AVAC ASF LIVE vaccine is a vaccine developed by Avac Vietnam Joint Stock Company to protect pigs from African Swine Fever (ASF). ASF is a highly contagious and frequently enough fatal viral disease affecting domestic and wild pigs. The AVAC vaccine aims to prevent the disease and reduce its impact on the pig population.
the AVAC ASF LIVE vaccine was authorized for use in pigs in July 2023, according to Nguyen Van Diep, General Director of Avac Vietnam Joint Stock Company.
3.Is the AVAC ASF LIVE vaccine safe and effective?
Yes, the vaccine has demonstrated both safety and effectiveness.
According to Nguyen Van Diep, the vaccine “has gained the confidence of government and livestock stakeholders due to its demonstrated safety and effectiveness.” Small-scale trials have already shown promising results.
- Robust Immune Response: 100% of vaccinated pigs developed antibodies against the ASF virus.
- Safety: No clinical abnormalities were observed in any of the vaccinated pigs, including those receiving a tenfold overdose..
- Low risk of transmission: Saliva and wastewater samples showed no detection of the ASF virus, thus no propagation.
4. What is the current stage of testing for the AVAC ASF LIVE vaccine?
Currently, Avac is conducting large-scale testing to evaluate the efficacy, safety, and impact on reproductive performance for sows and boars. This large-scale experimental model involves approximately 300 sows under controlled experimental conditions. The testing stage is specifically focused on evaluating reproductive performance post-vaccination. The company’s goal is to create a complete and transparent dataset.
5. What are the key findings from the large-scale testing?
The large-scale experimental model using 270 young sows showed the following encouraging initial results:
- Safety: All pigs (including those receiving a tenfold overdose) remained healthy with no clinical abnormalities as of April 2, 2025, 22 days after the first injection..
- strong Antibody Response: 100% of the vaccinated pigs developed antibodies against the African swine fever virus.
- no Virus detection: Saliva and wastewater samples showed no detection of the ASF virus,indicating a low risk of vaccine virus propagation in early testing.
6. How is avac ensuring transparency in its research?
Avac emphasizes transparency in its research by:
- Open Model: Building the experimental model openly and transparently.
- Inviting Stakeholders: Inviting scientists, international experts, industry associations, companies, and farmers to monitor the process.
- Comprehensive Data: Aiming to create a comprehensive and transparent dataset on the vaccine’s efficacy, safety, and impact on reproductive performance.
7. How is AVAC evaluating the vaccine’s impact on reproductive performance?
Avac is specifically designed to and currently is gathering results on reproductive performance post-vaccination. They anticipate inviting stakeholders back to the farm in approximately five months, during the pig breeding period, to directly assess reproductive efficiency.
8. What is the recommended vaccination protocol for the AVAC ASF LIVE vaccine?
the vaccination protocol is tailored for young and already-reproducing pigs:
- Young Reproductive Sows and Boars:
- Start vaccination at four weeks of age.
- Administer two injections, three weeks apart.
- Give the second injection two weeks before mating.
- Pigs that have already reproduced:
- Administer a booster vaccination in each reproductive cycle.
- Vaccinate 1 to 14 days before mating (approximately 2 to 3 weeks after delivery).
9. What are the future plans for the AVAC ASF LIVE vaccine?
the company has several future plans:
- They are inviting stakeholders back to the farm within approximately five months to assess reproductive efficiency.
- Avac is collaborating with the Central Veterinary Medication Test center I to establish criteria for evaluating ASF vaccines in reproductive pigs.
- They plan to propose official testing of the AVAC ASF LIVE vaccine in reproductive pigs to the Department of Animal Health (Ministry of agriculture and Habitat).
- It actively seeks collaborations with other international companies and laboratories to exchange data.
10. How long is the vaccine evaluation process?
The evaluation process for the ASF vaccine is expected to take approximately 5 to 6 months.
11. What is the significance of extending the vaccine’s use to reproductive pigs?
This is a strategic move to bolster the vaccine’s impact is key for overall herd protection and controlling the spread of ASF. By including reproductive pigs in the vaccination strategy, Avac aims to protect the next generation of pigs, ensuring a healthier and more productive pig population.
12. What is the General Director’s perspective on the vaccine based on the article?
Nguyen Van Diep, the General Director, expresses confidence in the vaccine. He mentions, “Recently, many farmers have proactively used the Avac ASF vaccine, not only in pigs, but also in sows, obtaining safe results.” This indicates a positive trend and confidence in the field data.
13. Where can I find more facts on current test results?
while the article presents some time-specific results, the best way to obtain the most up-to-date information is to regularly check the Avac Vietnam Joint stock Company’s official website. You can also search for scientific publications related to the AVAC ASF LIVE vaccine or contact the company directly for more information.
14. Can you provide a summary of key data from the testing?
Here’s a concise summary of key data from the recent testing of the AVAC ASF LIVE vaccine:
| Parameter | Result |
|---|---|
| safety (Clinical Signs) | All vaccinated pigs (including overdose group) healthy, with no abnormalities. |
| Antibody Response | 100% of vaccinated pigs developed antibodies. |
| Virus detection (Saliva/Wastewater) | No ASF virus detected. |